MNPR
Monopar Therapeutics Inc. Common Stock
stockNASDAQ
monopar therapeutics inc., a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the united states. it is involved in developing validive, a clonidine mucobuccal tablet that is in phase iii for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin, a topoisomerase ii-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and mnpr-101, a humanized monoclonal antibody for treating advanced solid cancers. the company has a collaboration grupo espaã±ol de investigaciã³n en sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and northstar medical radioisotopes, llc to develop radio-immuno-therapeutics targeting severe covid-19. monopar therapeutics inc. was founded in 2014 and is headquartered in wilmette, illinois.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 83.78 | 2026-10-07 | -12.76% | -5.713 |
| 1M | 108.32 | 2026-09-14 | -32.52% | 1.321 |
| 3M | 99.79 | 2026-07-14 | -26.76% | 1.792 |
| 6M | 57.92 | 2026-04-14 | +26.19% | 1.314 |
| 1Y | 95.29 | 2025-10-14 | -23.30% | 1.175 |
| 2Y | 5.39 | 2024-10-14 | +1256.03% | — |
| 5Y | 25.35 | 2021-10-14 | +188.32% | 0.767 |
Monopar Therapeutics Inc. Common Stock (NASDAQ:MNPR) stock price today is $73.09, and today's volume is 41,273. MNPR is up 1.401% today. The 30 day average volume is 156,110. MNPR market cap is $490.59M with 6.71M shares outstanding.